Published in Endoscopy on August 01, 2006
Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 0.99
Predictive factors for rebleeding and death in alcoholic cirrhotic patients with acute variceal bleeding: a multivariate analysis. World J Surg (2009) 0.93
Gut microbiota-related complications in cirrhosis. World J Gastroenterol (2014) 0.90
Comparison between endoscopic sclerotherapy and band ligation for hemostasis of acute variceal bleeding. World J Gastrointest Endosc (2011) 0.85
Endoscopic treatment of esophageal varices in patients with liver cirrhosis. World J Gastroenterol (2014) 0.84
Liver transplantation in a randomized controlled trial of emergency treatment of acutely bleeding esophageal varices in cirrhosis. Transplant Proc (2010) 0.81
Historical overview and review of current day treatment in the management of acute variceal haemorrhage. World J Gastroenterol (2014) 0.79
Emergency portacaval shunt versus rescue portacaval shunt in a randomized controlled trial of emergency treatment of acutely bleeding esophageal varices in cirrhosis--part 3. J Gastrointest Surg (2010) 0.78
Alcoholic versus nonalcoholic cirrhosis in a randomized controlled trial of emergency therapy of bleeding varices. J Surg Res (2010) 0.77
Endoscopic sclerotherapy for hemostasis of acute esophageal variceal bleeding. G Chir (2014) 0.75
Direct costs of care in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt for bleeding esophageal varices in cirrhosis--Part 4. J Gastrointest Surg (2010) 0.75
Sclerotherapy and esophageal variceal bleeding: time to forget it, or not? Endoscopy (2007) 0.75
Endoscopic treatment of bleeding esophageal varices. Endoscopy (2007) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Carcinoid tumour. Lancet (1998) 4.52
Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther (2014) 3.98
A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med (1995) 3.98
Gastric dysplasia: the Padova international classification. Am J Surg Pathol (2000) 3.66
Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology (1994) 3.15
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology (1997) 3.10
Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev (2007) 2.75
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol (2010) 2.50
Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J (1995) 2.39
Bacterial infection in the pathogenesis of variceal bleeding. Lancet (1999) 2.35
The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant (2012) 2.29
Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis (2002) 2.24
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther (2013) 2.22
Coagulation and fibrosis in chronic liver disease. Gut (2008) 2.22
Systematic review and meta-analysis of intraoperative versus preoperative endoscopic sphincterotomy in patients with gallbladder and suspected common bile duct stones. Br J Surg (2011) 2.13
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med (1983) 2.10
Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther (2006) 2.00
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet (1999) 1.98
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc (2000) 1.97
"Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology (1998) 1.95
Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther (2002) 1.94
Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut (2005) 1.93
Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol (2002) 1.92
A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology (2002) 1.90
An appraisal of the histopathological assessment of liver fibrosis. Gut (2006) 1.87
Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther (2005) 1.86
Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol (2005) 1.85
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol (1999) 1.76
Change in occurrence of paracetamol overdose in UK after introduction of blister packs. Lancet (2000) 1.75
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci (2000) 1.71
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2000) 1.66
Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol (2005) 1.64
Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut (1998) 1.63
Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev (2006) 1.63
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost (2010) 1.62
Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis (2000) 1.62
Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut (2006) 1.61
Early versus late surgery for ileo-caecal Crohn's disease. Aliment Pharmacol Ther (2007) 1.60
Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol (1999) 1.60
The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. Mamm Genome (1997) 1.59
Review article: portal vein thrombosis -- new insights into aetiology and management. Aliment Pharmacol Ther (2005) 1.59
Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology (1998) 1.57
Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther (2013) 1.56
Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant (2009) 1.52
Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut (2004) 1.50
A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut (2000) 1.48
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment Pharmacol Ther (2006) 1.48
Serum/ascites albumin gradient: its value as a rational approach to the differential diagnosis of ascites. Scand J Gastroenterol (1996) 1.48
Diurnal pattern of variceal bleeding in cirrhotic patients. J Hepatol (1993) 1.47
Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant (2006) 1.47
Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Dig Liver Dis (2001) 1.46
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.46
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig Liver Dis (2004) 1.46
Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther (2007) 1.45
Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis (2003) 1.44
The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly. Eur J Gastroenterol Hepatol (1997) 1.42
Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus. J Hepatol (1994) 1.40
Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. Am J Transplant (2013) 1.40
Systematic review of radiological imaging for hepatocellular carcinoma in cirrhotic patients. Br J Radiol (2004) 1.40
Infection, coagulation, and variceal bleeding in cirrhosis. Gut (2005) 1.39
Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis. Cancer (1991) 1.39
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study). Dig Liver Dis (2000) 1.39
Staple-line erosion: a common source of recurrent bleeding following stapled oesophageal transection. Br J Surg (1991) 1.39
Helicobacter pylori infection and growth delay in older children. Arch Dis Child (1997) 1.39
Who's for tips? Clin Radiol (1995) 1.38
Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Clin Radiol (1998) 1.38
The long term outcome of gastric non-invasive neoplasia. Gut (2003) 1.37
LeVeen shunt with wandering tip. Lancet (1991) 1.36
Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther (2008) 1.36
Idiopathic acute fatty liver of pregnancy in 12 patients. Q J Med (1982) 1.36
The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol (2000) 1.36
Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis (2004) 1.35
Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther (2009) 1.35
Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer (1999) 1.31
Controversies in the management of bleeding esophageal varices (1) N Engl J Med (1989) 1.30